Board of Directors

Board of Directors

Rich is one of the co-founders of MTG and is President and Chief Executive Officer. He has also been a Board Member of MTG’s parent company in Japan, Momotaro-Gene Inc., since 2012 and has managed the development of REIC technology for the company since 2008. Prior to MTG, Rich was President of a rapidly growing biotechnology consulting firm, Pacific-Link Consulting Inc., in San Diego, CA. Rich has been a development and regulatory expert for over 25 years holding senior management positions at Cadence Pharmaceuticals, Maxim Pharmaceuticals, AnGes Inc., Janssen Research Foundation and Somerset Pharmaceuticals. Prior to his career in industry, Rich was a New Drug Reviewer for the US Food and Drug Administration in the Division of Oncology and the Division of Neuropharmacologic Drug Products.

Wayne has a 30 year career in the pharmaceutical industry and held executive positions at Pfizer, Merck, Astra-Merck (now AstraZeneca) and Novartis followed by leadership roles in other healthcare related companies. His roles included Vice President, Marketing Operations (global) and Vice President, Far East and Pacific at Merck, founding Chief Executive Officer of Astra-Merck, and President and Chief Executive Officer of Novartis Pharmaceuticals Corporation, the US division of Novartis AG. Wayne later served as Chief Operating Officer of IMS Health, a market research data company from 1999 until 2000, and then became Chairman and Chief Executive Officer of Synavant, Inc. (a Nasdaq listed spin-out of IMS) that was acquired by Dendrite International in 2003. From 2005 -2008, Wayne served as Chief Executive Officer of Verispan LLC, a Joint venture of McKesson and Quintiles and leading provider of healthcare information and marketing services to the pharmaceutical industry. Verispan was acquired by SDI Health and later merged into IMS. Most recently, Wayne was Chairman of the Board of NuPathe Inc. that was acquired by TEVA in early 2014. Wayne currently serves as a director of InfuSystem Holdings, Inc.(INFU), and Strategic Diversified Opportunities Inc. (SDOI) a shell company remaining after the sale of the Life Sciences business of Strategic Diagnostics (SDIX) to OriGene. Previous board roles include Chairman of Noven Pharmaceuticals, Chairman of Transkaryotic Therapies, and Lead Independent Director of Matria Healthcare (each of these companies was acquired). Wayne was a member of Executive Committee of PhRMA, the pharmaceutical industry association, from 1997-1999.

Hitoshi Shiomi is the CEO of Momotaro-Gene Inc., the Japanese Patent company of MTG Biotherapeutics Inc. in the US. Mr. Shiomi has been responsible for managing Momotaro-Gene’s efforts in developing the REIC technology for the past 8 years. He has an extensive business background in both international and Japanese healthcare businesses.
Professor Hiromi Kumon (MD, PhD) is the scientific founder of Momotaro-Gene Inc. and previously Chief of Urology at Okayama University Medical School. He is currently the Director of the Innovation Center at Okayama for Nanobio-targeted Therapy (ICONT). Dr. Kumon has lead the development of the REIC technology since 2005 and has been instramental in guiding the company into clinical research.